Epioxa® is now available

Effective July 1, 2026 Permanent HCPCS code for Epioxa: J2789

Each kit contains 2 billable units.
Download our Billing and Coding Guide for Epioxa.

Corneal Health Solutions

Transforming Corneal Care Through Early Detection, Education, and Innovation

We are transforming the standard of care for patients with keratoconus through our commitment to addressing important unmet clinical needs in corneal health—placing a strong emphasis on early detection and timely intervention to minimize unnecessary vision loss.

Through education efforts, and partnerships with advocacy organizations and medical societies, we aim to raise awareness, drive earlier diagnosis, and improve access to Keratoconus care.

With inspired innovation, a customer-centric focus, and robust market access support programs, we are in constant pursuit of developing proven solutions in corneal health that empower eye care professionals to identify Keratoconus earlier, intervene sooner, and deliver optimal care that helps preserve long-term visual outcomes.

Contact Sales Rep

What are the signs and symptoms of keratoconus, and how can corneal cross-linking help?

Explore Patient Resources for Keratoconus Treatment Options

View Patient Website

Contact Us Today

Explore additional information about Corneal treatment

Request
More Info

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Address*

IMPORTANT SAFETY INFORMATION

Contraindications

EPIOXA® HD and EPIOXA® are contraindicated in patients with known hypersensitivity to benzalkonium chloride (BAC) or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.

Warnings and Precautions

Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.

Adverse Reactions

The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.

Dosage and Administration

EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use.
EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use.
EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only.
Refer to the O2n System Operator’s Manual and Boost Goggles User Guide for device instructions.

INDICATIONS AND USAGE

EPIOXA® HD (riboflavin 5’-phosphate ophthalmic solution) 0.239% and EPIOXA® (riboflavin 5’-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n™ System and the Boost Goggles®.

Please see full Prescribing Information for EPIOXA HD and EPIOXA at www.Epioxa.com.
You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also call Glaukos at 1-888-404-1644.